Novartis biosimilar copycat takes aim at Amgen's drug Enbrel

Posted by Owen Ajayi-Isaac

Date: October 02, 2015

Leave a comment

204 Views

Share this on WhatsApp

ZURICH (Reuters) – The U.S. Food and Drug Administration has accepted Novartis unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s blockbuster Enbrel drug, the Swiss drugmaker said on Friday.

Source: ReuterBusiness

Share

Share this on WhatsApp

Related posts

• GE reopens parts of prior debt offerings to raise $3 billion

  June 08, 2020

• AstraZeneca contacted Gilead over potential megamerger: Bloomberg News

  June 07, 2020

• Lufthansa CEO promises Germans a 'homecoming guarantee'

  June 07, 2020

• BA, Ryanair, easyJet protest over 'wholly unjustified' UK quarantine plan

  June 07, 2020

• Emirates, Etihad extend temporary salary cuts to September

  June 07, 2020

• AstraZeneca approached Gilead about potential merger – Bloomberg News

  June 07, 2020

• Rosneft says no change to dividend policy despite lower state stake

  June 07, 2020

• HSBC warns it could face reprisals in China if UK bans Huawei equipment: Telegraph

  June 06, 2020

• Volkswagen considering more cost cuts to cope with downturn

  June 06, 2020

• Exclusive: Malaysia – Even $3 billion not enough to settle 1MDB case with Goldman

  June 06, 2020

• OPEC and allies to agree one-month extension to output cuts

  June 06, 2020

• Exclusive: Buyout firm Sycamore Partners in talks to buy J.C. Penney – sources

  June 06, 2020